<DOC>
	<DOCNO>NCT00170573</DOCNO>
	<brief_summary>Pegylated liposomal doxorubicin ( PLD ) formulation approve treatment recurrent ovarian cancer ( ROC ) . Toxic skin reaction report dose-limiting toxicity impact patient ' quality life ( QoL ) . The primary aim study optimise toxicity profile choose biweekly schedule PLD Furthermore , QoL investigate . Secondary objective study evaluate response rate new regimen .</brief_summary>
	<brief_title>Caelyx Biweekly Heavily Pretreated Patients With Relapsed Ovarian Cancer</brief_title>
	<detailed_description />
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<criteria>Patients â‰¥ 18 year age recurrent ovarian , peritoneal , tubal cancer prior treatment platinum paclitaxel eligible trial . Eastern Cooperative Oncology Group ( ECOG ) performance status le 3. renal function ( serum creatinine 1.25 time upper limit normal , glomerular filtration rate great 60 ml/min ) liver function ( AST/ ALT three time upper limit normal , bilirubin concentration 1.25 upper limit normal ) bone marrow function ( neutrophil count great 1.5 x 109/l , platelet count great 100 x 109/l ) . patient 4 chemotherapy medical history severe cardiac disease</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>biweekly schedule PLD - Ovarian cancer - pegylated liposomal doxorubicin -quality life - Toxic skin reaction</keyword>
</DOC>